pharmaphorum2d
Is GSK’s Blenrep heading for a renaissance?
Results from that are due in the second half of 2024. GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.
GSK’s GSK’227 receives FDA BTD for treating adults with relapsed osteosarcoma
GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for GSK5764227, GSK’227, ...
FierceBiotech1mon
GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets
GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis. The two-stranded collaboration will ...
MarketWatch1mon
GSK outperforms market despite losses on the day
Shares of GSK PLC GSK inched down 0.69% to £13.74 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.86% to 8,280.36.
Nature1y
GSK welcomes partners with innovative technologies to accelerate vaccine R&D
GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...
Yahoo Finance6d
GSK’s Nucala Gains Approval in China for CRSwNP
GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...